Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

PHASE2CompletedINTERVENTIONAL
Enrollment

189

Participants

Timeline

Start Date

January 23, 2015

Primary Completion Date

July 14, 2017

Study Completion Date

July 14, 2017

Conditions
Respiratory Syncytial Virus
Interventions
DRUG

Presatovir

Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube

DRUG

Placebo

Tablets administered orally or via nasogastric tube

Trial Locations (68)

Unknown

Mayo Clinic Arizona, Phoenix

City of Hope, Duarte

UCLA David Geffen School of Medicine, Los Angeles

Stanford University, Stanford

Emory University, Atlanta

NorthSide Medical Center, Atlanta

Northwestern University, Chicago

University of Chicago, Chicago

Loyola University, Maywood

John Hopkins, Baltimore

Dana Farber Cancer Institute, Boston

University of Massachusetts Memorial Cancer Center, Boston

University of Michigan, Ann Arbor

Wayne State University, Detroit

University of Minnesota, Minneapolis

Washington University, St Louis

Memorial Sloan Kettering, New York

New York Presbyterian Hospital Cornell Medical Center, New York

Duke University, Durham

University Hospital Case Medical, Cleveland

Oregon Health Sciences University, Portland

Vanderbilt University Medical Center, Nashville

MD Anderson Cancer Center, Houston

Texas Transplant Institute (SCRI), San Antonio

University of Utah, Salt Lake City

Fred Hutchison Cancer Research Center, Seattle

Medical College of Wisconsin, Milwaukee

Westmead Hospital, Westmead

Royal Brisbane & Women's Hospital, Herston

Royal Melbourne Hospital, Melbourne

Hospital de Clínicas de Porto Alegre, Porto Alegre

Fundacao Faculdade Regional Medicina de Sao Jose do Rio Preto, São Paulo

Fundação Antonio Prudente - Hospital do Câncer AC Camargo, São Paulo

Hospital Israelita Albert Einstein, São Paulo

Hospital Santa Marcelina, São Paulo

Hospital Universitario USP, São Paulo

Instituto Brasileiro de Controle do Câncer-IBCC, São Paulo

Hopital Maisonneuve-Rosemont, Montreal

Tom Baker Cancer Centre, Calgary

CHU de Bordeaux, Bordeaux

Hopital Saint-Louis, APHP, Paris

Hopital Foch, Suresnes

Institut Universitaire du Cancer Oncopole, Toulouse

Universitatsklinikum Wurzburg, Würzburg

Soroka Medical Center, Beersheba

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Chaim Sheba Medical Center, Ramat Gan

Tel Aviv Sourasky Medical Center, Tel Aviv

VUmc cancer center, Amsterdam

Erasmus Medical Center (Rotterdam), Rotterdam

Singapore General Hospital, Singapore

UMC National University Health System, Singapore

Asan Medical Center, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul Saint Mary's Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Hospital universitario Virgen del Rocio, Seville

Karolinska Institutet, Stockholm

University Clinic Basel, Basel

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

China Medical University Hospital, Taichung

National Taiwan University Hospital, Taipei

Chang Gung Medical Foundation-LinKou Branch, Taoyuan District

Leeds Teaching Hospitals Trust, Leeds

King's College Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02254408 - Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract | Biotech Hunter | Biotech Hunter